Advertisement

Advertisement

SE:ONCO Stock Latest News

Company AnnouncementsOncopeptides Marks Growth Phase as 2025 Annual Report Highlights Pepaxti Momentum

PremiumCompany Announcements

Oncopeptides Sets May Date and Rules for 2026 AGM Participation

18d ago

PremiumCompany Announcements

Oncopeptides Showcases Promising NK-Cell Engager Data for Multiple Myeloma at AACR 2026

20d ago

Oncopeptides Boosts Share Capital After Rights Issue to Support Cancer Drug Push

PremiumCompany Announcements

Oncopeptides Boosts Share Capital After Rights Issue to Support Cancer Drug Push

1M ago

Oncopeptides Raises SEK 190 Million in Partially Guaranteed Rights Issue

PremiumCompany Announcements

Oncopeptides Raises SEK 190 Million in Partially Guaranteed Rights Issue

2M ago

Oncopeptides Launches Real-World MARINA Study for Pepaxti in Germany

PremiumCompany AnnouncementsOncopeptides Launches Real-World MARINA Study for Pepaxti in Germany

2M ago

Real-World Data Bolsters Oncopeptides’ Pepaxti as Bridging Therapy in Multiple Myeloma

Company Announcements

Real-World Data Bolsters Oncopeptides’ Pepaxti as Bridging Therapy in Multiple Myeloma

2M ago

Oncopeptides Wins Fast-Track Status for First PDC Trial in Glioblastoma

Company Announcements

Oncopeptides Wins Fast-Track Status for First PDC Trial in Glioblastoma

2M ago

Oncopeptides AB Balances Growth, Cash Crunch in Earnings

PremiumCompany Announcements

Oncopeptides AB Balances Growth, Cash Crunch in Earnings

2M ago

Oncopeptides launches SEK 200m rights issue to fund Pepaxti rollout and glioblastoma push

PremiumCompany Announcements

Oncopeptides launches SEK 200m rights issue to fund Pepaxti rollout and glioblastoma push

2M ago

Oncopeptides Doubles 2025 Sales and Raises Capital to Drive Glioblastoma Push

PremiumCompany Announcements

Oncopeptides Doubles 2025 Sales and Raises Capital to Drive Glioblastoma Push

2M ago

Oncopeptides Sets Date for 2025 Year-End Results Presentation

PremiumCompany Announcements

Oncopeptides Sets Date for 2025 Year-End Results Presentation

3M ago

Oncopeptides Lifts 2025 Sales but Delays Cash-Flow Break-Even to 2027

PremiumCompany AnnouncementsOncopeptides Lifts 2025 Sales but Delays Cash-Flow Break-Even to 2027

4M ago

Oncopeptides Drug Pepaxti Shows Strong Efficacy in High-Risk Multiple Myeloma

Company Announcements

Oncopeptides Drug Pepaxti Shows Strong Efficacy in High-Risk Multiple Myeloma

4M ago

Oncopeptides AB Establishes Nomination Committee for 2026 AGM

Company Announcements

Oncopeptides AB Establishes Nomination Committee for 2026 AGM

5M ago

Expert Panel Endorses Oncopeptides’ Pepaxti for Myeloma Treatment

PremiumCompany Announcements

Expert Panel Endorses Oncopeptides’ Pepaxti for Myeloma Treatment

6M ago

Oncopeptides AB Earnings Call Highlights Growth and Challenges

PremiumCompany Announcements

Oncopeptides AB Earnings Call Highlights Growth and Challenges

6M ago

Oncopeptides AB Reports Strong Q3 2025 Growth and Strategic Milestones

PremiumCompany Announcements

Oncopeptides AB Reports Strong Q3 2025 Growth and Strategic Milestones

6M ago

Oncopeptides’ NK Cell Engager Study to be Presented at ASH

PremiumCompany Announcements

Oncopeptides’ NK Cell Engager Study to be Presented at ASH

6M ago

Oncopeptides Adjusts Share Structure Amid Strategic Incentive Program

PremiumCompany AnnouncementsOncopeptides Adjusts Share Structure Amid Strategic Incentive Program

6M ago

Oncopeptides to Release Q3 2025 Financial Report

Company Announcements

Oncopeptides to Release Q3 2025 Financial Report

6M ago

Oncopeptides to Host Strategic Capital Markets Update

Company Announcements

Oncopeptides to Host Strategic Capital Markets Update

6M ago

Trending

S&P 500

―

Dow Jones

―

Nasdaq 100

―

More Trending Stocks >